2025 · 4th Quarter (Oct 1 - Dec 31)

SANOFI, U.S.

Filed by WILLIAMS AND JENSEN, PLLC.

Open official filing

Source-reported fields

Filing overview

Type: 4th Quarter - Report
Posted: Jan 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: WILLIAMS AND JENSEN, PLLC
Client: SANOFI, U.S.
Filing UUID: 481e6282-7ffb-42f3-b52c-435ad97981f1
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

MMM · Medicare/Medicaid

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Literal federal measure citations: H.R. 1

MED · Medical/Disease Research/Clinical Labs

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.

HCR · Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

TAX · Taxation/Internal Revenue Code

Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.